An approach to the etiology of metabolic syndrome

Angélica M Muñoz; Gabriel Bedoya; Claudia Velásquez

doi:10.25100/cm.v44i1.813

##plugins.block.makeSubmission.linkLabel##

An approach to the etiology of metabolic syndrome

https://doi.org/10.25100/cm.v44i1.813

Metabolic syndrome obesity insulin resistance genetics ancestry.

PDF HTML Copyright

Published: Mar 12, 2013

Issue: Vol. 44 No. 1 (2013)

Section Reviews

Publcation metrics

501 | 508 | 71

Authors

Angélica M Muñoz Universidad de Antioquia

Gabriel Bedoya Universidad de Antioquia

Claudia Velásquez Universidad de Antioquia

Abstract

Increased prevalence of obesity in the world, especially accumulation of abnormal amounts of visceral fat predisposes to insulina resistance, which is the central role of metabolic syndrome (MS). Obesity can deregulate the intracellular signaling of insulina due to the production of inflammatory substances, chemo attractant proteins, adipokines and molecules that trigger hormonal mediator potentials for destabilization of signal transduction, leading to metabolic disorders such as hyperglycemia, hypertension, and dyslipidemia. The complexity of the MS and of the genetic mechanisms involved in its etiology derives from the combination of variants on genes involved and environmental factors that predispose it. The purpose of this paper is to review the effects of obesity in molecular and biochemical responses that trigger insulin resistance and its relation to some candidate genes and the ancestral component of the population.

Author Biographies

Angélica M Muñoz, Universidad de Antioquia

Nutricionist Dietician. PhD Student Basic Biomedical Science. Research Group Food and Human Nutrition. Antioquia University

Gabriel Bedoya, Universidad de Antioquia

Biologist . Mg Biology. Research Group Molecular Genetic -GENMOL. Antioquia University

Claudia Velásquez, Universidad de Antioquia

Nutricionist Dietician. Mg Basic Biomedical Science. Research Group Food and Human Nutrition. Antioquia University

How to Cite

Muñoz, A. M., Bedoya, G., & Velásquez, C. (2013). An approach to the etiology of metabolic syndrome. Colombia Medica, 44(1), 57–63. https://doi.org/10.25100/cm.v44i1.813

References

1.Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008; 28: 629-36.

2. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a oint interim statement of the International Diabetes Federation ask Force on Epidemiology and Prevention; National Heart, ung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and international Association for the study of obesity. Circulation. 2009; 120: 1640-5.

3. WHO. Global strategy on diet, physical activity and health: Obesity and overweight. Genova; WHO; 2004. Available in : http://www.who.int/dietphysicalactivity/strategy/eb11344/strategy_english_web.pdf.

4. Schelbert KB. Comorbidities of obesity. Prim Care. 2009; 36: 271-85.

5. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010; 42: 937-48.

6. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007; 316: 889-94.

7. Li S, Zhao JH, Luan J, Luben RN, Rodwell SA, Khaw KT, et al. Cumulative effects and predictive value of common obesity-susceptibility variants identified by genome-wide association studies. Am J Clin Nutr. 2010; 91: 184-90.

8. Zhao J, Bradfield JP, Li M, Wang K, Zhang H, Kim CE, et al. The role of obesity-associated loci identified in genome-wide association studies in the determination of pediatric BMI. Obesity. 2009; 17: 2254-7.

9. Bauer F, Elbers CC, Adan RA, Loos RJ, Onland-Moret NC, Grobbee DE, et al. Obesity genes identified in genome-wide association studies are associated with adiposity measures and potentially with nutrient-specific food preference. Am J Clin Nutr. 2009; 90: 951-9.

10. Berthoud HR, Morrison C. The brain, appetite, and obesity. Annu Rev Psychol. 2008; 59: 55-92.

11. Phillips LK, Prins JB. The link between abdominal obesity and the metabolic syndrome. Curr Hypertens Rep. 2008; 10: 156-64.

12. Lindgren CM, Heid IM, Randall JC, Lamina C, Steinthorsdottir V, Qi L, et al. Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. PloS Genet. 2009; 5: e1000508.

13. Plum L, Belgardt BF, Bruning JC. Central insulin action in energy and glucose homeostasis. J Clin Invest. 2006; 116(7): 1761-6.

14. Gerozissis K. Brain insulin, energy and glucose homeostasis; genes, environment and metabolic pathologies. Eur J Pharmacol. 2008; 585: 38-49.

15. Cai D, Dhe-Paganon S, Melendez PA, Lee J, Shoelson SE. Two new substrates in insulin signaling, IRS5/DOK4 and IRS6/DOK5. J Biol Chem. 2003; 278: 25323-30

16. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab. 2002; 283: E413-22.

17. Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest. 2000; 106: 165-9.

18. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001; 414: 799-806

19. Sun XJ, Crimmins DL, Myers MG, Jr., Miralpeix M, White MF. Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1. Mol Cell Biol. 1993; 13: 7418-28.

20. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006; 7: 85-96.

21. Liu YF, Paz K, Herschkovitz A, Alt A, Tennenbaum T, Sampson SR, et al. Insulin stimulates PKCzeta -mediated phosphorylation of insulin receptor substrate-1 (IRS-1). A self-attenuated mechanism to negatively regulate the function of IRS proteins. J Biol Chem. 2001; 276: 14459-65.

22. Mothe I, Van Obberghen E. Phosphorylation of insulin receptor substrate-1 on multiple serine residues, 612, 632, 662, and 731, modulates insulin action. J Biol Chem. 1996; 271: 11222-7.

23. Pederson TM, Kramer DL, Rondinone CM. Serine/threonine phosphorylation of IRS-1 triggers its degradation: possible regulation by tyrosine phosphorylation. Diabetes. 2001; 50: 24-31.

24. Ogihara T, Isobe T, Ichimura T, Taoka M, Funaki M, Sakoda H, et al. 14-3-3 protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain. J Biol Chem. 1997; 272: 25267-74.

25. Moeschel K, Beck A, Weigert C, Lammers R, Kalbacher H, Voelter W, et al. Protein kinase C-zeta-induced phosphorylation of Ser318 in insulin receptor substrate-1 (IRS-1) attenuates the interaction with the insulin receptor and the tyrosine phosphorylation of IRS-1. J Biol Chem. 2004; 279: 25157-63.

26. Mussig K, Fiedler H, Staiger H, Weigert C, Lehmann R, Schleicher ED, et al. Insulin-induced stimulation of JNK and the PI 3-kinase/mTOR pathway leads to phosphorylation of serine 318 of IRS-1 in C2C12 myotubes. Biochem Biophys Res Commun. 2005; 335: 819-25.

27. Gao Z, Hwang D, Bataille F, Lefevre M, York D, Quon MJ, et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem. 2002; 277: 48115-21.

28. Youngren JF. Regulation of insulin receptor function. Cell Mol Life Sci. 2007; 64: 873-91.

29. Sako Y, Grill VE. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology. 1990; 127: 1580-9.

30. Iyer A, Fairlie DP, Prins JB, Hammock BD, Brown L. Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol. 2010; 6: 71-82.

31. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011; 11: 85-97.

32. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000; 106: 171-6.

33. Nieto-Vazquez I, Fernandez-Veledo S, Kramer DK, Vila-Bedmar R, Garcia-Guerra L, Lorenzo M. Insulin resistance associated to obesity: the link TNF-alpha. Arch Physiol Biochem. 2008; 114: 183-94.

34. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004; 306: 457-61.

35. Muoio DM, Newgard CB. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol. 2008; 9: 193-205.

36. Chaudhary K, Buddineni JP, Nistala R, Whaley-Connell A. Resistant hypertension in the High-Risk Metabolic Patient. Curr Diab Rep. 2011; 11: 41-6

37. Shu XO, Long J, Cai Q, Qi L, Xiang YB, Cho YS, et al. Identification of new genetic risk variants for type 2 diabetes. PloS Genet. 2010; 6 pii: e1001127

38. Levine F, Itkin-Ansari P. Beta-cell regeneration: neogenesis, replication or both? J Mol Med. 2008; 86(3): 247-58.

39. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006; 444: 840-6.

40. Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Want you like to know? Endocr Rev. 2005; 26: 898-915.

41. Lyssenko V, Lupi R, Marchetti P, Del Guerra S, Orho-Melander M, Almgren P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest. 2007; 117: 2155-63.

42. Xiang J, Li XY, Xu M, Hong J, Huang Y, Tan JR, et al. Zinc transporter-8 gene (SLC30A8) is associated with type 2 diabetes in Chinese. J Clin Endocrinol Metab. 2008; 93: 4107-12.

43. Basson J, Simino J, Rao DC. Between candidate genes and whole genomes: time for alternative approaches in blood pressure genetics. Curr Hypertens Rep. 2012; 14: 46-61.

44. Rader DJ. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med. 2007; 120: S12-8.

45. Wang H. Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab. 2009; 297: E271–88.

46. Pan WH, Chen JW, Fann C, Jou YS, Wu SY. Linkage analysis with candidate genes: the Taiwan young-onset hypertension genetic study. Hum Genet. 2000; 107: 210-5.

47. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010; 466: 707-13.

48. Silva-Zolezzi I, Hidalgo-Miranda A, Estrada-Gil J, Fernandez-Lopez JC, Uribe-Figueroa L, Contreras A, et al. Analysis of genomic diversity in Mexican Mestizo populations to develop genomic medicine in Mexico. Proc Natl Acad Sci U S A. 2009; 106: 8611-6.

49. Villarreal-Molina MT, Aguilar-Salinas CA, Rodriguez-Cruz M, Riano D, Villalobos-Comparan M, Coral-Vazquez R, et al. The ATP-binding cassette transporter A1 R230C variant affects HDL cholesterol levels and BMI in the Mexican population: association with obesity and obesity-related comorbidities. Diabetes. 2007; 56: 1881-7.

50. Acuna-Alonzo V, Flores-Dorantes T, Kruit JK, Villarreal-Molina T, Arellano-Campos O, Hunemeier T, et al. A functional ABCA1 gene variant is associated with low HDL-cholesterol levels and shows evidence of positive selection in Native Americans. Hum Mol Genet. 2010; 19: 2877-85.

51. Goodarzi MO, Guo X, Taylor KD, Quinones MJ, Saad MF, Yang H, et al. Lipoprotein lipase is a gene for insulin resistance in Mexican Americans. Diabetes. 2004; 53: 214-20.

52. Caamaño LJ, Saavedra N, Jaramillo PC, Lanas C, Lanas F, Salazar LA. Polimorfismo Pro72Arg del gen TP53 se asocia a enfermedad coronaria en individuos Chilenos. Rev Chil Cardiol. 2009; 28: 151-7.

53. Franco-Hincapié L, Duque CE, Parra MV, Gallego N, Villegas A, Ruiz-Linares A, et al. Asociación de variantes en genes de las proteínas desacoplantes con diabetes mellitus tipo 2 en una población del nordeste colombiano. Biomédica. 2009; 29: 108-18.

54. Prudente S, Morini E, Trischitta V. Insulin signaling regulating genes: effect on T2DM and cardiovascular risk. Nat Rev Endocrinol. 2009; 5: 682-93.

55. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003; 163: 427-36.

56. Douglas JG, Thibonnier M, Wright JT, Jr. Essential hypertension: racial/ethnic differences in pathophysiology. J Assoc Acad Minor Phys. 1996; 7: 16-21.

57. Brown SA, Hutchinson R, Morrisett J, Boerwinkle E, Davis CE, Gotto AM, Jr., et al. Population admixture associated with disease prevalence in the Boston Puerto Rican health study US communities. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb. 1993; 13: 1139-58.

58. Chakraborty R, Weiss KM. Admixture as a tool for finding linked genes and detecting that difference from allelic association between loci. Proc Natl Acad Sci U S A. 1988; 85: 9119-23.

59. Lai CQ, Tucker KL, Choudhry S, Parnell LD, Mattei J, Garcia-Bailo B, et al. Population admixture associated with disease prevalence in the Boston Puerto Rican health study. Hum Genet. 2009; 125: 199-209.

60. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998; 21: 518-24.

Usage statistics